8-K: Ligand Pharmaceuticals Announces Strong Q4 and Full Year 2023 Results, Reaffirms 2024 Guidance

Ligand Pharmaceuticals reported robust financial results for Q4 and full year 2023, driven by strong royalty revenue and core Captisol sales, and reaffirmed its positive outlook for 2024.

Summary

• Ligand Pharmaceuticals reported total revenues of $28.1 million in Q4 2023, compared to $50.4 million in Q4 2022, which included $23.5 million in COVID-19 related Captisol sales.
• Excluding COVID-19 related sales, Q4 2022 revenue was $26.8 million.
• Royalties in Q4 2023 were $22.5 million, up from $22.0 million in Q4 2022.
• Core Captisol sales (excluding COVID-19) were $3.9 million in Q4 2023, compared to $3.3 million in Q4 2022.
• Net income from continuing operations in Q4 2023 was $18.2 million ($1.03 per diluted share), compared to a net loss of $14.5 million ($0.86 per share) in Q4 2022.
• Adjusted net income from continuing operations in Q4 2023 was $24.4 million ($1.38 per diluted share), compared to $23.5 million ($1.36 per diluted share) in Q4 2022.
• For the full year 2023, total revenues were $131.3 million, compared to $196.2 million in 2022 (including $88.1 million in COVID-19 related Captisol sales).
• Excluding COVID-19 related sales, 2022 revenue was $108.2 million.
• Royalties for 2023 were $83.9 million, up from $72.5 million in 2022.
• Core Captisol sales were $28.4 million in 2023, compared to $16.4 million in 2022.
• Net income from continuing operations for 2023 was $53.8 million ($3.03 per diluted share), compared to a net loss of $5.2 million ($0.31 per share) in 2022.
• Adjusted net income from continuing operations for 2023 was $107.4 million ($6.09 per diluted share), compared to $82.2 million ($4.79 per diluted share) in 2022.
• Ligand reaffirmed its 2024 guidance, expecting royalties of $90-$95 million, Captisol sales of $25-$27 million, and contract revenue of $15-$20 million, resulting in total revenue of $130-$142 million and adjusted EPS of $4.25-$4.75.

Sentiment

Score: 8

Explanation: The overall sentiment is positive, reflecting strong financial performance, positive clinical developments, and a reaffirmed positive outlook for 2024. While some setbacks were noted, they appear to be manageable and do not significantly detract from the positive momentum.

Positives

• FDA approval of ZELSUVMI for molluscum contagiosum provides a new revenue stream.
• Merck’s V116 vaccine received FDA priority review, potentially leading to royalties for Ligand.
• Sermonix Pharmaceuticals’ licensing agreement with Henlius expands the reach of lasofoxifene in China.
• Travere Therapeutics reported positive results for FILSPARI and plans an sNDA submission.
• Eisai obtained approval for a Captisol-enabled injection formulation of Fycompa in Japan.
• Palvella Therapeutics received Breakthrough Therapy Designation for QTORIN for microcystic lymphatic malformations.
• Viking Therapeutics presented positive Phase 2b results for VK2809 in NASH.
• Verona Pharma secured a $400 million debt financing facility to support growth.

Negatives

• Travere Therapeutics’ DUPLEX study results were insufficient for an FSGS indication for FILSPARI.
• Aldeyra Therapeutics received a CRL from the FDA for reproxalap for dry eye disease.

Risks

• Dependence on collaborative partners for revenue creates uncertainty.
• Competition in acquiring royalties and developing therapeutics could limit growth.
• Regulatory approvals and market acceptance of partnered products are not guaranteed.
• Dependence on a single supplier for Captisol poses a supply chain risk.
• Partners may shift development focus or experience delays, impacting Ligand’s revenue.
• Intellectual property challenges could affect product exclusivity.
• Integration of acquisitions may present challenges and costs.
• General economic conditions and litigation could negatively impact the company.

Future Outlook

Ligand reaffirmed its 2024 guidance, projecting total revenue of $130-$142 million and adjusted EPS of $4.25-$4.75, driven by expected growth in royalties, Captisol sales, and contract revenue. The company expects continued momentum in clinical and regulatory events across its partnered assets.

Management Comments

• 2023 was a transformative year for Ligand, both operationally and financially. We refocused the company to be a lean-infrastructure, high-margin business.
• We enhanced our deal making capabilities with the strengthening of our senior team and opening of a Boston office.
• These initiatives will help us execute on a larger scale and continue to expand our portfolio through a focus on life science royalty opportunities.
• We are now well positioned and resourced to close on multiple new investments.
• We also saw important clinical and regulatory events across our existing partnered assets and expect this momentum will continue in 2024 and beyond.

Industry Context

Ligand’s performance reflects the broader trend in the biopharmaceutical industry of focusing on partnerships and licensing agreements to share risk and accelerate drug development. The company’s emphasis on royalty acquisitions positions it to benefit from the success of its partners’ products.

Stakeholder Impact

• Shareholders are likely to benefit from the positive financial results and growth prospects.
• The FDA approval of ZELSUVMI benefits patients with molluscum contagiosum.
• Partnerships and licensing agreements create opportunities for collaborators.

Next Steps

• Travere Therapeutics plans to submit an sNDA for FILSPARI in IgAN in Q1 2024.
• Aldeyra Therapeutics anticipates resubmitting an NDA for reproxalap in the first half of 2024.
• Travere Therapeutics plans to re-engage the FDA regarding FILSPARI for FSGS in 2024.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Financial Results, Q4 2023, Full Year 2023, Earnings, Royalties, Captisol, Biopharmaceuticals, Drug Development, Partnerships, FDA Approvals, ZELSUVMI, V116, FILSPARI, Fycompa, reproxalap, QTORIN, VK2809